Skip to main content

Kailera Therapeutics, Inc.

corporate_fare Company Profile

Kailera Therapeutics, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed KLRA - Latest Insights

KLRA
Apr 23, 2026, 8:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Bain Capital Affiliate Discloses 17.4% Stake, Plans Active Role Post-IPO
Sentiment: Positive
View Wiseek Article
KLRA
Apr 23, 2026, 7:34 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Bain Capital Affiliate Discloses 20.3% Stake in Kailera Therapeutics Post-IPO, Plans Active Role
Sentiment: Positive
View Wiseek Article
KLRA
Apr 20, 2026, 6:10 PM EDT
Filing Type: 4
Importance Score:
9
Bain Capital Investors Makes Over $580M Post-IPO Investment in Kailera Therapeutics
Sentiment: Positive
View Wiseek Article
KLRA
Apr 20, 2026, 6:08 PM EDT
Filing Type: 4
Importance Score:
9
Director & 10% Owner Koppel Adam Invests Over $550M Post-IPO in Kailera Therapeutics
Sentiment: Positive
View Wiseek Article
KLRA
Apr 20, 2026, 6:01 PM EDT
Filing Type: 4
Importance Score:
9
Bain Capital Life Sciences Acquires Over $550M in Kailera Therapeutics Post-IPO
Sentiment: Positive
View Wiseek Article
KLRA
Apr 20, 2026, 6:00 PM EDT
Filing Type: 4
Importance Score:
9
Director & 10% Owner Makes Substantial Post-IPO Purchase
Sentiment: Positive
View Wiseek Article
KLRA
Apr 20, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
9
Kailera Therapeutics Finalizes $718.8M IPO, Underwriters Fully Exercise Option
Sentiment: Positive
View Wiseek Article
KLRA
Apr 17, 2026, 4:06 PM EDT
Filing Type: 424B4
Importance Score:
9
Kailera Therapeutics Finalizes $625M Initial Public Offering at $16.00 Per Share to Fund Obesity Pipeline
Sentiment: Positive
View Wiseek Article
KLRA
Apr 16, 2026, 7:25 PM EDT
Source: GlobeNewswire
Importance Score:
9
Kailera Therapeutics Prices IPO at $16/Share, Raising $625M Ahead of Nasdaq Debut
Sentiment: Positive
View Wiseek Article